ReviewFrontiers in oncology2026
Molecular characteristics and advances in precision therapeutics for HR-positive and HER2-low breast cancer.
Review in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
HR-positive HER2-low-expressing breast cancer is a unique subtype that has been refined from the traditional HER2 binary classification system in recent years, accounting for nearly 60% of the overall incidence of breast cancer. It has significant value for precise diagnosis and treatment research. This review systematically elaborates on the epidemiological characteristics, biological basis, diagnostic technology progress, and treatment strategy evolution of this subtype. HR-positive HER2-low-expressing breast cancer is characterized by the dominance of the estrogen receptor pathway and the core molecular feature of the intersection of HER2 low-expression signals. Its diagnosis requires a balance between the fundamental role of endocrine therapy and the precise screening of anti-HER2 targeted therapy. In terms of diagnosis, the initial screening by immunohistochemistry combined with fluorescence
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.